CTRI/2012/12/003238
Completed
Phase 4
A prospective, open-label, multicentre, non-comparative, observational post marketing surveillance study evaluating effectiveness and tolerability of Trioptal® (Oxcarbazepine) in patients with generalized tonic-clonic seizures as monotherapy in routine clinical practice in India
ovartis India Ltd0 sites500 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Patients with generalized tonic-clonic seizures.
- Sponsor
- ovartis India Ltd
- Enrollment
- 500
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with a history of generalized tonic\-clonic seizures.
Exclusion Criteria
- •Contraindications like hypersensitivity to the active substance or to any of the excipients mentioned in the local prescribing information for Trioptal.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Study to evaluate the effectiveness and tolerability of Carbamazepine (TEgrital®) as Monotherapy in patients with generalized tonic-clonic seizures.Health Condition 1: null- Naïve patients with generalized tonic-clonic seizuresCTRI/2013/10/004071ovartis India Limited493
Active, not recruiting
Phase 1
This is a non-comparative study that aims to evaluate and confirm the effects of the Effimia® contraceptive pill on intermenstrual bleeding.Combined Oral Contraceptives (COC)MedDRA version: 20.0Level: SOCClassification code 10014698Term: Endocrine disordersSystem Organ Class: 10014698 - Endocrine disordersTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2021-003027-15-ITITALFARMACO S.P.A.228
Recruiting
Phase 4
TRIOX: A post marketing study on the effects and safety of Trioptal in patients with newly diagnosed epilepsyCTRI/2010/091/001239ovartis India LimitedSandoz House, 5th floorShivsagar EstateDr. Annie Besant RoadIndia500
Active, not recruiting
Not Applicable
A prospective, multicentre, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third lineAdvanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third lineMedDRA version: 17.1Level: PTClassification code 10033158Term: Ovarian epithelial cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-000491-14-ESAB Science56
Active, not recruiting
Phase 1
Study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third lineMedDRA version: 20.0 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-000491-14-SKAB Science80